Alnylam Pharmaceuticals Inc (ALNY)

Alnylam Pharmaceuticals Inc (ALNY) stock plummeted by 10.19% due to concerns arising from a key clinical trial design change, overshadowing a minor Q4 revenue miss.

• Q4 Results and Financial Performance: Alnylam reported Q4 total revenue of $439.7 million, reflecting a 31% increase year over year, slightly below analysts' average estimate of $442.9 million. The company posted a net loss of $137.9 million, or $1.10 per share (GAAP), with a non-GAAP net loss of $96.6 million, or $0.77 per share.
• *Concerns Over Clinical Trial Design**: Investor worries stemmed from Alnylam's announcement of an updated statistical analysis plan and revised timing for its Helios-B phase 3 study evaluating vutrisiran in treating ATTR-CM. Changes include focusing on outcome measures in overall and monotherapy populations, tweaking secondary endpoints, and extending the trial by up to three months.
• Investor Reaction and Analysis: Investors interpreted the revised trial plan as a potential lack of management confidence in the Helios-B results, leading to the stock's sharp decline. While conservative investors may shy away due to the inherent risks, more aggressive investors could view the dip as a buying opportunity, considering the company's solid sales growth and management's confidence in the trial's outcome.

Alnylam Pharmaceuticals' stock fell sharply by 8.78% to $193.06, as a split advisory panel recommended FDA approval for their heart disease treatment, Onpattro, but with conditions. The panel indicated its potential usefulness for patients unresponsive to Pfizer's tafamidis, causing a drop of 8.8% in Alnylam's stock to $193.06 below its 50-day moving average.

https://www.investors.com/news/technology/alnylam-stock-tumbles-on-dashed-hopes-of-rivaling-pfizer-in-heart-disease-treatment/?src=A00220